Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
Immunovant, Inc. (IMVT) had Cash Flow from Financial Activities of $595.76M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-147.86M |
|
-- |
|
-- |
|
$159.55M |
|
$-159.55M |
|
$8.85M |
|
$-150.70M |
|
$-150.70M |
|
$-147.86M |
|
$-147.86M |
|
$-147.86M |
|
$-147.86M |
|
$-159.55M |
|
$-159.46M |
|
182.42M |
|
182.42M |
|
$-0.72 |
|
$-0.72 |
|
| Balance Sheet Financials | |
$948.82M |
|
$0.44M |
|
$8.20M |
|
$957.01M |
|
$104.42M |
|
-- |
|
-- |
|
$104.42M |
|
$852.59M |
|
$852.59M |
|
$852.59M |
|
203.94M |
|
| Cash Flow Statement Financials | |
$-407.31M |
|
$-0.01M |
|
|
Cash Flow from Financial Activities |
$595.76M |
$713.97M |
|
$902.11M |
|
$188.14M |
|
$55.72M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-407.32M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-17.34% |
|
-17.34% |
|
-15.45% |
|
-17.34% |
|
$4.18 |
|
$-2.23 |
|
$-2.23 |
|